Skip to main content
Medical cannabis safety: welcome step, now include patients | PatientsCann UK®
Independent view PatientsCann UK® is a patient-led Community Interest Company. We are not a member of the Cannabis-Based Medicines Association or the Medical Cannabis Clinicians Society, and we have no commercial link with either. This is not medical or legal advice.

In short

What is the Cannabis-Based Medicines Association?

The Cannabis-Based Medicines Association (CBMA) is a new UK trade association for licensed operators in cannabis-based medicines, launched on 16 November 2026. Its founding members include Curaleaf, Glass Pharms and Wellford, and voting rights are reserved for licensed UK operators. With the Medical Cannabis Clinicians Society, it has written to Professor Henrietta Hughes OBE, England’s Patient Safety Commissioner, following her public comments in October, offering to work on prescribing safeguards and standards of care (CBMA, 2026).

  • What we welcome: industry and clinicians coming together to put patient safety first, build better evidence and raise standards.
  • Our concern: patients and patient-led groups are not yet part of the conversation, and only licensed operators can vote in the association.
  • What we offer: patient insight and experience, to help make new standards work for the people they are meant to protect.

The news

What happened

On 16 November 2026, the Cannabis-Based Medicines Association launched with a commitment to strengthen patient safety, raise industry standards and support the responsible integration of cannabis-based medicines into mainstream healthcare (CBMA, 2026).

The association says it is dedicated only to cannabis-based medicines, unlike broader cannabis industry bodies. Its work is built around three priorities: putting patient safety first, strengthening the clinical evidence base through collaboration with clinics, and raising standards across the industry.

On the same day, the CBMA joined the Medical Cannabis Clinicians Society (MCCS) in writing to Professor Henrietta Hughes OBE, England’s Patient Safety Commissioner. The letter follows the Commissioner’s recent public comments about regulation and prescribing practices in the sector, and offers constructive engagement on improving prescribing safeguards and standards of care. The two organisations say they will work more closely to encourage responsible practice, support established clinical guidance, and explore greater consistency and transparency across the sector (CBMA, 2026).

What we welcome

Why this is a welcome step

This is a positive step. It builds on the work the Cannabis Industry Council has already led with licensed operators and clinicians to raise standards and develop guidance across the sector, and we are pleased to see operators and clinicians respond to the Patient Safety Commissioner’s concerns constructively, by offering to work with her on the solutions.

The Cannabis Industry Council brings businesses, clinicians, advocacy groups and patients together, and PatientsCann UK® is proud to be a member. That mix of voices is what gives its work weight. A trade association for licensed operators has a narrower role, speaking for the companies it represents, which is why patients need to be heard alongside it.

The CBMA’s three priorities, putting patient safety first, strengthening the evidence base and raising standards, are ones we share. We have spent years asking for proper checks before prescribing, better follow-up, consistent quality of medicine and real data on what works. The MCCS has already published good practice guidance, and closer work between the two bodies could help make that the norm across every clinic.

Patients are the people most affected when prescribing goes wrong, and the people who lose most when it is restricted badly. An industry that takes safety seriously is good news for all of us.

The background

Why is this happening now?

The CBMA and MCCS letter is a response to public comments from the Patient Safety Commissioner in October. She said the growth of private prescribing has outpaced the systems needed to keep patients safe, and that responsibility is spread across too many organisations, leaving gaps in information and oversight (Kirby, 2026).

The numbers show how fast things have moved. Almost two million unlicensed cannabis items (1,967,268) were issued on private prescription in England between June 2025 and May 2026. About three quarters of them were flower (Press Association, 2026).

Her comments came alongside a coroner’s report into the death of Oliver Robinson, aged 34, from Bury, who had been prescribed medical cannabis privately by Curaleaf Clinic. The coroner found the prescribing decision relied on an outdated GP record. Curaleaf said it complies with regulatory standards and has improved information-sharing with other healthcare teams (Press Association, 2026). His family is calling for “Oliver’s Law” to tighten prescribing rules.

This is not about whether these medicines should be available to patients who may benefit from them.
Professor Henrietta Hughes OBE, Patient Safety Commissioner for England (Kirby, 2026)

If you need to talk. Samaritans are there day and night on 116 123, free to call. If you would rather not speak, text SHOUT to 85258. If you are worried about your mental health and your prescription, your clinic or GP can review it with you.

Our concern

The missing voice: patients

Our one real concern is who is in the conversation. The new association reserves voting rights for licensed UK operators: the companies that grow, supply, prescribe and dispense. The letter to the Commissioner comes from that industry and from clinicians. Patients are at the heart of what it sets out to achieve, but are not yet part of the discussion.

That matters, because patients see medical cannabis from a side that clinics and suppliers do not. We are the ones stopped by police, questioned by employers, refused by landlords, sent products we have never seen, and priced out of treatment. Those experiences are part of patient safety too, and they rarely reach a boardroom.

Involving patients would also build trust. Hearing directly from the people the standards are meant to protect would give this work real credibility with patients, and help make sure the changes that follow are ones patients can get behind.

The Patient Safety Commissioner’s role was created by Parliament to promote the safety of patients and the importance of patients’ views (Medicines and Medical Devices Act 2021). We hope she will make sure patient voices are heard directly in this work, not passed on through industry.

We want this to work. If the conversation is about our safety and our medicine, patients should be at the table helping to shape it. Nothing about us without us.
Mohammad Wasway, Managing Director, PatientsCann UK®

Working together

How patients can help this succeed

Bring patients into the talks with the Commissioner
Patients and patient-led organisations can add what no one else can to work on prescribing safeguards and standards of care. They should be involved from the start.
Hear from patients directly
The Patient Safety Commissioner and the MCCS can make sure patients are heard in their own words as safeguards are developed, not only through industry. Patient-led organisations are ready to help.
Protect access while improving safety
Stronger safeguards should target poor practice, not make life harder for the many patients whose treatment is stable and working.

We are ready to help. We will be writing to the CBMA, the MCCS and the Patient Safety Commissioner to welcome this work, offer patient insight, and ask how patients can be involved from here.

FAQs

Common questions

What is the Cannabis-Based Medicines Association?

The Cannabis-Based Medicines Association (CBMA) is a UK trade association for licensed operators in cannabis-based medicines, launched on 16 November 2026. It says its priorities are patient safety, a stronger clinical evidence base and higher industry standards.

Who are the CBMA’s founding members?

The CBMA says its founding members include Curaleaf, Glass Pharms and Wellford. Voting rights are reserved for licensed UK operators.

How is the CBMA different from the Cannabis Industry Council?

The CBMA describes itself as dedicated only to cannabis-based medicines, with voting rights reserved for licensed UK operators. The Cannabis Industry Council is a broader body whose members include businesses, clinicians, advocacy groups and patients.

Can patients vote in the CBMA?

No. According to the CBMA’s launch announcement, voting rights are reserved for licensed UK operators. This means patients and patient-led groups have no vote on its decisions.

What is the Medical Cannabis Clinicians Society?

The Medical Cannabis Clinicians Society (MCCS) is a UK body for clinicians involved in medical cannabis. It has published a good practice guide and has joined the CBMA in writing to the Patient Safety Commissioner.

Who is the Patient Safety Commissioner?

Professor Henrietta Hughes OBE is the Patient Safety Commissioner for England. The role was created by the Medicines and Medical Devices Act 2021 to promote patient safety and the importance of patients’ views on the safety of medicines and medical devices.

Why should patients be involved in medical cannabis safety decisions?

Patients live with the results of prescribing decisions every day, from how treatment is reviewed to the quality and cost of their medicine. Their experience shows risks and problems that industry and clinicians may not see, so patients and patient-led organisations should help shape any new safeguards.

Your experience counts

Tell us what patient safety means to you. Your experiences help us make the case for patients to be heard.

References

References follow the Harvard style.

  1. Cannabis-Based Medicines Association (CBMA) (2026) Medical cannabis industry and UK clinicians join forces to improve access to safe and effective patient care [Press release]. London, 16 November.
  2. Kirby, J. (2026) ‘Experts issue medical cannabis warning to millions of Britons’,